Safety of Antihypertensive Medication for the Management of Non‐Severe Gestational Hypertension Among Pregnant Individuals in Botswana—Emulating a Series of Target Trials
Paediatric and Perinatal Epidemiology · 2026
DOI: 10.1111/ppe.70079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Paediatric and Perinatal Epidemiology, 2026. Verfasst von Julia D DiTosto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Antihypertensive Agents, Hypertension, Pregnancy-Induced. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NIAID NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Background
Data on antihypertensive medication for non‐severe gestational hypertension may suffer from immortal time and selection bias. Emulating target trials can prevent these biases by aligning follow‐up with treatment initiation.
Objectives
We estimated the safety of antihypertensive medication initiation for the treatment of non‐severe gestational hypertension on adverse birth outcomes in Botswana using sequential target trial emulation.
Methods
Data from the Tsepamo study (2014–2022), capturing birth outcomes at government delivery sites in Botswana, was used to examine antihypertensive medication initiation ≥ 24 weeks gestation for non‐severe gestational hypertension (140–159 systolic or 90–109 diastolic blood pressure ≥ 20 weeks gestation without chronic hypertension). Sequential weekly target trial emulation compared initiation versus no initiation during 24–35 weeks' gestation on the risk of stillbirth and birth of infant small for gestational age (SGA), with secondary outcomes including very SGA, preterm birth, very preterm birth, neonatal death, and severe gestational hypertension. For each trial, eligible individuals were without chronic hypertension, had not previously initiated antihypertensive medication and had ≥ 2 non‐severe blood pressure readings, at least one within 1 week of trial start. Log‐binomial models estimated gestational week‐specific and pooled risk ratios (RR) with 95% confidence intervals (CI) using bootstrapping.
Results
Of eligible individuals, there were 1676 antihypertensive initiator ‘person‐trials’ and 5211 non‐initiator ‘person‐trials’. In the pooled analysis, the adjusted RR for stillbirth and SGA comparing initiators to non‐initiators was 0.92 (0.68, 1.19) and 1.09 (0.97, 1.23), respectively. The pooled adjusted RR for secondary outcomes were: very SGA, 1.05 (95% CI 0.88, 1.25); preterm birth, 1.09 (95% CI 0.96, 1.22); very preterm birth, 1.05 (95% CI 0.78, 1.47); neonatal death, 1.23 (95% CI 0.68, 2.24); severe gestational hypertension, 0.88 (95% CI 0.74, 1.07).
Conclusions
In this retrospective cohort study, antihypertensive medication initiation between 24 and 35 weeks' gestation for non‐severe gestational hypertension was not associated with increased risk of adverse birth outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Botswana-Harvard AIDS Initiative Partnership for HIV Research and Education, Gaborone, Botswana.
- Division of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Department of Obstetrics and Gynecology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
- Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA.
ORCID-Profile: Sunni L Mumford
Förderung
- NICHD NIH HHS
- NIAID NIH HHS
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
DiTosto, J. D., Zash, R., Jacobson, D. L., Johnson, K., Diseko, M., Mayondi, G., Mabuta, J., Mmalane, M., Makhema, J., Mumford, S. L., Lockman, S., Shapiro, R., & Caniglia, E. C. (2026). Safety of Antihypertensive Medication for the Management of Non‐Severe Gestational Hypertension Among Pregnant Individuals in Botswana—Emulating a Series of Target Trials. Paediatric and Perinatal Epidemiology. https://doi.org/10.1111/ppe.70079
Vancouver
DiTosto JD, Zash R, Jacobson DL, Johnson K, Diseko M, Mayondi G, et al. Safety of Antihypertensive Medication for the Management of Non‐Severe Gestational Hypertension Among Pregnant Individuals in Botswana—Emulating a Series of Target Trials. Paediatric and Perinatal Epidemiology. 2026. doi:10.1111/ppe.70079
BibTeX
@article{DiTosto2026,
author = {DiTosto, Julia D and Zash, Rebecca and Jacobson, Denise L and Johnson, Katherine and Diseko, Modiegi and Mayondi, Gloria and Mabuta, Judith and Mmalane, Mompati and Makhema, Joseph and Mumford, Sunni L and Lockman, Shahin and Shapiro, Roger and Caniglia, Ellen C},
title = {Safety of Antihypertensive Medication for the Management of Non‐Severe Gestational Hypertension Among Pregnant Individuals in Botswana—Emulating a Series of Target Trials},
journal = {Paediatric and Perinatal Epidemiology},
year = {2026},
doi = {10.1111/ppe.70079}
}
EUVIMED